SEC Filing Summary: Synthetic Blood International, Inc. (10-K)
Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Fiscal year ended April 30, 2007.
Business Stage: Development-stage enterprise with no commercial revenues.
Primary Focus: Development of Oxycyte, a perfluorocarbon-based synthetic blood substitute currently in Phase II clinical trials. Other products, Fluorovent (lung treatment) and a glucose biosensor, are on hold pending additional financing.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 |
|---|---|---|
| Revenue | $0 (Other Income: $120,027) | $0 (Other Income: $67,872) |
| Net Loss | $(3,330,870) | $(4,066,593) |
| Accumulated Deficit | $(31,020,194) | $(27,689,324) |
| Cash and Equivalents | $16,234 | $382 |
| Working Capital | $(362,286) | $(269,965) |
| Total Liabilities | $1,845,634 | $424,572 |
| Stockholders' Equity | $(23,112) | $186,216 |
Expense Breakdown (FY 2007): Research & Development ($752,614), General & Administrative ($1,019,795), Interest Expense ($1,678,488).
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $736,000 compared to FY 2006, primarily due to reduced General & Administrative expenses (down 20%) and lower R&D spending.
- Liquidity Deterioration: While cash on hand increased slightly from $382 to $16,234, the company moved from positive stockholders' equity ($186,216) to a deficit ($23,112) due to the net loss exceeding capital contributions.
- Debt Increase: Total liabilities surged from $424,572 to $1.85 million, driven by the issuance of short-term notes payable ($1.29 million principal) and convertible debentures to fund operations.
- Interest Expense: Interest charges remained high at $1.68 million, largely due to amortization of original issue discounts and the fair value of warrants attached to debt instruments.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management and auditors explicitly state there is "substantial doubt" about the company's ability to continue as a going concern. The company lacks working capital to fund operations in fiscal year 2008.
- Financing Needs: Immediate financing is required to cover administrative expenses and ongoing Oxycyte testing. Management is seeking equity and/or debt financing, but no assurance of availability exists.
- Clinical Progress: Phase II trials for Oxycyte are ongoing (expected through 2008). A trial for severe brain injury was completed with good results; a sickle cell disease protocol is on clinical hold for revisions.
- Strategic Risks: The company is a one-product focus. Failure of Oxycyte to gain FDA approval or secure funding would likely result in business cessation. Development of other products is paused.
- Stock Dilution: Significant dilution is expected as the company relies on issuing warrants and convertible notes to raise capital. Approximately 86.1 million shares are reserved for conversion/exercise of existing instruments.
Investor Verification Checklist
- Cash Runway: Verify current cash balance and immediate access to capital, as the filing states the company cannot fund FY 2008 operations without new financing.
- Debt Covenants: Review terms of the $1.29 million in short-term notes and convertible debentures, specifically regarding interest rates, maturity dates, and conversion features that may force equity dilution.
- Clinical Trial Status: Confirm the current status of the Phase II Oxycyte trials and the resolution of the clinical hold on the sickle cell disease protocol.
- Going Concern Opinion: Review the latest audit report to confirm if the "substantial doubt" regarding the going concern status persists or has been resolved.
- Share Count: Monitor the number of shares outstanding and the potential dilution from the 78+ million warrants and 6+ million options currently outstanding.